Veto overturn effort for SCHIP by Democrats

21 October 2007

A showdown between the Democratic party-controlled US Congress and the Republican administration in the White House is due on October 18, when the House of Representatives is scheduled to vote on a proposal to overturn President George W Bush's veto of the extension of the States Children's Health Insurance Program.

Analysts at Lehman Brothers estimate that the vote is unlikely to succeed in securing the two-thirds majority of 435 Representatives that is required to overrule Pres Bush's veto. According to WashingtonWatch.com, the cost of the SCHIP renewal would be $1,608.01 per family. In a marked shift in public opinion, the group now estimates that support for the expanded form of the SCHIP is down to 49% with a small majority, 51%, opposing the Democrat-inspired coverage expansion proposals.

Pres Bush vetoed the SCHIP renewal bill, only the fourth item of legislation blocked by him but the third in the past year, on October 3.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight